A battery-powered, fully integrated microfluidic platform quantifies post-transplant viral infections from raw urine at point of care within about one hour. The system avoids extraction steps and targets faster turnaround for clinical monitoring of viral reactivation and early infection risks. For transplant centers, shortening time-to-result can improve decision-making around immunosuppression adjustment and antiviral initiation. The clinical utility hinges on analytical sensitivity, robustness in real-world urine matrices, and integration with laboratory workflows. The platform also signals a broader push toward sample-to-answer diagnostics that can reduce lab capacity constraints and help standardize monitoring across sites.
Get the Daily Brief